Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesCopyBotsEarn
BIO Protocol founder interprets DeSci, three projects will be launched on Launchpad soon

BIO Protocol founder interprets DeSci, three projects will be launched on Launchpad soon

ChaincatcherChaincatcher2024/11/19 23:00
By:PANews

We need to fundamentally reshape outdated scientific institutions and processes, accelerate everything related to biology, and build a global, inclusive scientific network.

Original source: Paul Kohlhaas X account

Original author: Paul Kohlhaas , founder of BIO Protocol

Compiled by: Zen, PANews

Bitcoin, as the first decentralized digital currency system, enables permissionless value exchange; Ethereum allows anyone to deploy their own programs through the introduction of smart contracts, achieving permissionless code execution.

Many people invest in cryptocurrencies to maintain their autonomy and to prevent the slow and quiet erosion of their freedoms. A similar movement is forming in the fields of science and medicine, as the freedom to innovate, self-experiment, and disseminate science has been eroded by a broken biomedical research and development system.

The Current System is Unfavorable for Disease Cures

In 2018, Goldman Sachs released a report titled "The Genomic Revolution," questioning whether curing patients is a sustainable business model. Goldman Sachs cited Gilead Sciences as an example; the company generated $12.5 billion in revenue in 2015 due to its effective hepatitis C treatment, but as more patients were cured, sales plummeted to $4 billion in the following years.

BIO Protocol founder interprets DeSci, three projects will be launched on Launchpad soon image 0

Chronic disease treatments, such as pain management with opioids, can ensure recurring revenue but often lead to patient dependency on drugs rather than addressing the root problem. Their addictive nature has also led to widespread drug abuse and dependency. Opioid-related deaths, particularly those caused by prescription opioids, have become a significant public health issue in the United States.

Scientists Focus on Fundraising Rather Than Research

Imagine a scenario where software developers spend most of their time fundraising instead of writing code. What would that look like?

Most Scientific Talent is Underutilized

Due to a lack of foundational upgrades in science and technology, we are unable to achieve solarpunk—a highly harmonious society between humans and nature, filled with sustainability, abundant resources, and innovative idealism.

These dilemmas have led to a scientific development process filled with various resistances and problems, rather than the "scientific fantasy" world we aspire to. So, what if we could build a decentralized and self-organizing scientific world? A self-sovereign scientific system driven by open data and liquid markets, with disease cures as its core goal.

Molecule DAO and BIO Protocol

Molecule is a protocol that brings scientific intellectual property (IP) on-chain; BIO is an engine that provides launch and acceleration for on-chain scientific communities (BioDAOs), composed of scientists, patients, and investors. BioDAO focuses on a specific scientific field or disease, developing research, drugs, products, and other on-chain intellectual property. For example, VitaDAO has funded multiple projects related to longevity science and research, including the VITA-FAST project developed by the Vikorolchuk lab at Newcastle University.

The BIO Protocol team has built the first batch of BioDAOs across multiple scientific fields. According to Dune data, when Paul Kohlhaas spoke last week, the total market cap of BioDAOs was less than $100 million, but by November 18, it had exceeded $230 million.

BIO aims to assist scientists, patients, and biotech founders in establishing on-chain scientific communities, including tokenomics design, community building, funding, and liquidity support. BIO token holders can vote to incorporate DAOs into the network, similar to a community-owned accelerator that helps the best teams stand out and launch their communities on-chain. Upcoming projects on the BIO Launchpad include:

  • Curetopia : Targeting the $1 trillion rare disease market, its team member Eric Perlstein, a Y Combinator alumnus, Harvard PhD, and rare disease entrepreneur, has pushed a drug to Phase III clinical trials with just $5 million in funding, whereas this typically costs over $100 million.
  • Long COVID Labs : Accelerating cure solutions for over 100 million long COVID patients worldwide, led by former Stanford neuroscientist Rohan Dixit.
  • Quantum Biology DAO : Building quantum microscopes to observe quantum biological phenomena, led by MIT PhD Clarice D. Aiello, one of the world's leading quantum biology scientists.

BIO Protocol founder interprets DeSci, three projects will be launched on Launchpad soon image 1

To promote the development of the protocol, BIO recently held a Genesis event, inviting users to deposit supported DeSci tokens in exchange for BIO tokens. The Genesis event raised $33 million for the BIO treasury, and as DeSci token prices rose, the treasury funds have now exceeded $53 million. Additionally, BIO has received investment from Binance Labs.

The Role of IP-NFTs

The BIO protocol plays a central role in the BioDAO network, where each BioDAO is developing drugs and therapies related to specific diseases or treatments, and these research outcomes exist in the form of tokenized scientific intellectual property (IP). Typically, each stage of drug development has historically been kept confidential from the public, while BioDAOs aim to leverage blockchain technology to make this process more open and transparent.

BIO Protocol founder interprets DeSci, three projects will be launched on Launchpad soon image 2

IP-NFTs are the foundation supporting this new model, allowing anyone to put intellectual property on-chain, making it programmable, tradable, liquid, and rich in data. Essentially, IP-NFTs are containers for intellectual property. Once the IP is fully validated, it can be split into IPT (IP tokens) and used as governance tokens, enabling individuals to participate as active stakeholders in the scientific process.

For example, Vita-RNA, supported by VitaDAO, focuses on developing new mRNA gene therapies, led by biotech experts Michael Torres and Anthony Schwartz. The Vita-RNA project received $300,000 in initial funding, but its VITARNA token's market cap has already grown to over $27 million. After one of Vita-RNA's main drug candidates showed activity in vitro (in the lab), its price began to rise on Uniswap.

Future Outlook for BIO

The BIO Protocol is inspired by the bio/acc movement, which aims to accelerate the development of biology and disrupt many traditional perceptions of healthcare. Biotechnology is the new matrix of life itself. We must fundamentally reshape outdated scientific institutions and processes, accelerate all biologically related research, and build a global, participatory scientific network.

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Locked for new tokens.
APR up to 10%. Always on, always get airdrop.
Lock now!

You may also like

MicroStrategy Buys $1.5B in Bitcoin, Raising BTC Holdings at 439K

The company's BTC holdings are now worth over $46.7 billion at current prices

CyrptoRo2024/12/18 01:00

Bitcoin Hit a New ATH Above $107K, as BTC ETFs Recorded 13 Consecutive Inflow Days

Since November 27, BTC ETFs recorded almost $6 billion in inflows, amidst rising institutional interest

CyrptoRo2024/12/18 01:00

AAVE drops below $360

Cointime2024/12/18 00:55